09:38 AM EST - Antibe Therapeutics Inc : Announced the initiation of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar Q1 2024. Antibe Therapeutics Inc
shares T.ATE are trading unchanged at $0.45.
